License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2021

License And Collaboration Agreements [Abstract]

Summary of Research and Development Costs Related to Collaboration and License Agreements

The following table summarizes the impact of the research and development costs related to the collaboration and license agreements on the Company’s consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2020 and 2021. For details on the structure and accounting treatment for the Company’s collaboration and license agreements, refer to the annual consolidated financial statements and notes contained in the 2020 Form 10-K.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2021		2020		2021
	(in thousands)				(in thousands)
Cullinan Oncology - Adimab	$	—	$	46	$	318	$	46
Amber - MIT		—		—		276		71
Apollo - Wistar		—		—		304		—
Florentine - Tubingen		912		—		912		—
Pearl - Taiho		531		—		531		3,000
	$	1,443	$	46	$	2,341	$	3,117